Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer

Benedetta Conte, Francesca Poggio, Lucia Del Mastro

Research output: Contribution to journalReview article


Introduction: The role of ovarian function suppression (OFS) through luteinizing hormone-releasing hormone agonists (LHRHa) in addition to tamoxifen has been questioned until recently. In 2015, two large clinical trials led to a paradigm shift in the adjuvant endocrine treatment of premenopausal women, introducing the use of LHRHa plus tamoxifen (or aromatase inhibitor, AI) into current clinical practice. Areas covered: The present review aims to provide an in-depth overview of the role of LHRHa+tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer (HR+BC). Expert opinion: The addition of LHRHa to endocrine treatment (either tamoxifen or AI) is effective in premenopausal women who are at high risk of relapse. To date, no clear recommendations are available for the choice between LHRHa+tamoxifen and LHRH+AI. Although recent data showed better DFS with LHRHa+AI, other issues should be considered: 1) approximately 20 out of 100 women do not reach complete OFS with LHRHa+AI; 2) there is no extended endocrine therapy option that can be applied to women who received 5 years of LHRHa+AI and remained premenopausal at the end of the fifth year. Long-term results of the SOFT-TEXT study are needed to establish if LHRHa+AI is superior to LHRHa+tamoxifen.

Original languageEnglish
Pages (from-to)1357-1362
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Issue number13
Publication statusPublished - Sep 2 2017



  • aromatase inhibitors
  • breast cancer
  • Gonadotropin-releasing hormones analogs
  • ovarian function suppression
  • premenopausal women
  • tamoxifen

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this